Literature DB >> 9950139

Placental biogenic amine transporters: in vivo function, regulation and pathobiological significance.

T T Nguyen1, Y T Tseng, B McGonnigal, J P Stabila, L A Worrell, S Saha, J F Padbury.   

Abstract

The biogenic amine transporters are part of a large family of plasma membrane transporters. These carriers mediate the re-uptake of neurotransmitters from the synaptic cleft and plasma compartments. Re-uptake process is inhibited by drugs like cocaine, fluoxetine and tricyclic antidepressants. There are specific transporters for norepinephrine, epinephrine, dopamine and serotonin. The placenta expresses the norepinephrine and serotonin transporters, which is unusual as they are otherwise expressed predominantly in neuronal tissue. Fetal catecholamine clearance rate is higher than under any other physiological conditions and is mediated in large measure by the placental transporters. The high intrauterine catecholamine secretion and clearance rates are part of the unique fetal neuroendocrine milieu. They condition the fetus to a high capacity for catecholamine secretion in the early postnatal period when elevated sympathoadrenal system activity is vital for postnatal survival. Because of the prominent catecholamine clearance rate, the fetus is vulnerable to the adverse effects of re-uptake inhibitors. Understanding the mechanisms of expression and regulation of placental biogenic amine transporters is important to the pathobiology of fetal conditions associated with elevated catecholamine levels or intrauterine exposure to uptake inhibitors like cocaine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950139     DOI: 10.1053/plac.1998.0348

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  7 in total

Review 1.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

Review 2.  The Placenta as a Mediator of Stress Effects on Neurodevelopmental Reprogramming.

Authors:  Stefanie L Bronson; Tracy L Bale
Journal:  Neuropsychopharmacology       Date:  2015-08-07       Impact factor: 7.853

3.  Embryo-placento-maternal interaction and biomarkers: from diagnosis to therapy--a workshop report.

Authors:  N G Than; M J Paidas; S Mizutani; S Sharma; J Padbury; E R Barnea
Journal:  Placenta       Date:  2007-03-23       Impact factor: 3.481

4.  Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.

Authors:  Brent J Thompson; Tammy Jessen; L K Henry; Julie R Field; Karen L Gamble; Paul J Gresch; Ana M Carneiro; Rebecca E Horton; Peter J Chisnell; Yekaterina Belova; Douglas G McMahon; Lynette C Daws; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

5.  Prenatal cocaine use and maternal depression: effects on infant neurobehavior.

Authors:  Amy L Salisbury; Barry M Lester; Ronald Seifer; Linda Lagasse; Charles R Bauer; Seetha Shankaran; Henrietta Bada; Linda Wright; Jing Liu; Ken Poole
Journal:  Neurotoxicol Teratol       Date:  2006-12-14       Impact factor: 3.763

Review 6.  Fetal effects of psychoactive drugs.

Authors:  Amy L Salisbury; Kathryn L Ponder; James F Padbury; Barry M Lester
Journal:  Clin Perinatol       Date:  2009-09       Impact factor: 3.430

Review 7.  Drugs of abuse and human placenta.

Authors:  Vadivel Ganapathy
Journal:  Life Sci       Date:  2010-10-16       Impact factor: 5.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.